Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Staten Island, New York. It focuses on developing a new class of small molecule antibiotics to treat difficult-to-treat bacterial infections caused by priority pathogens. The company's proprietary approach targets the DNA polymerase IIIC enzyme to inhibit DNA replication in Gram-positive bacteria.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Selling, General & Administrative Expenses
6,257
8,719
8,534
7,339
Research & Development Expenses
1,835
5,404
6,044
4,754
Operating Profit
(8,092)
(14,123)
(14,578)
(12,093)
Interest and Investment Income
125
20
—
—
Total Non-Operating Income
125
20
—
—
Income Before Provision for Income Taxes
(7,967)
(14,103)
(14,578)
(12,093)
Consolidated Net Income
(7,967)
(14,103)
(14,578)
(12,093)
Net Income Attributable to Common Shareholders
(7,967)
(14,103)
(14,578)
(12,093)
Basic EPS
-5.32
-17.45
-23.00
-22.40
Diluted EPS
-5.32
-17.45
-23.00
-22.40
Basic Weighted Average Shares Outstanding
1,499
808
634
541
Diluted Weighted Average Shares Outstanding
1,499
808
634
541
Shares Outstanding
2,348
852
688
580
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
7,556
3,707
7,474
9,112
Total Cash and Cash Equivalents
7,556
3,707
7,474
9,112
Other Receivables
48
51
129
—
Total Trade Receivables
48
51
129
—
Other Current Assets
85
100
106
265
Total Current Assets
7,690
3,858
7,709
9,377
Total Assets
7,690
3,858
7,709
9,377
Accounts Payable
2,421
3,243
3,042
2,062
Total Current Liabilities
2,421
3,243
3,042
2,062
Total Liabilities
2,421
3,243
3,042
2,062
Common Stock
—
—
14
12
Additional Paid-in Capital
80,555
67,936
57,871
45,944
Retained Earnings
(75,288)
(67,322)
(53,219)
(38,641)
Total Common Shareholders' Equity
5,269
615
4,667
7,315
Total Shareholders' Equity
5,269
615
4,667
7,315
Total Liabilities and Shareholders' Equity
7,690
3,858
7,709
9,377
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(7,967)
(14,103)
(14,578)
(12,093)
Share-Based Compensation Expense
1,570
3,436
3,766
3,302
Changes in Accounts Payable
(409)
200
981
1,218
Changes in Other Operating Activities
18
84
30
30
Cash from Operating Activities
(6,788)
(10,383)
(9,801)
(7,542)
Issuance of Common Shares
10,638
6,616
8,163
3,695
Net Issuance / (Repurchases) of Common Shares
10,638
6,616
8,163
3,695
Other Financing Activities
(1)
—
—
—
Cash from Financing Activities
10,637
6,616
8,163
3,695
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash